Melanoma in solid organ transplant recipients

F. O. Zwald, L. J. Christenson, E. M. Billingsley, N. C. Zeitouni, D. Ratner, J. Bordeaux, M. J. Patel, M. D. Brown, C. M. Proby, S. Euvrard, C. C. Otley, T. Stasko, ITSCC

    Research output: Contribution to journalArticle

    64 Citations (Scopus)

    Abstract

    This manuscript outlines estimated risk and clinical course of pretransplant MM, donor-transmitted MM and de novo MM posttransplantation and includes an analysis of risk factors for metastasis, data from clinical studies and current and proposed management. MM in situ and thin melanoma (< 1 mm) in the transplant population has similar recurrence and survival estimates to those in the general population. A minimum wait time of 2 years prior to transplantation is suggested for MM with a Breslow depth < 1 mm and no clinical evidence of metastasis. More advanced MM may adopt a more aggressive course in transplant recipients. Sentinel lymph node biopsy may be of additional prognostic benefit. Revision of immunosuppression in the management of de novo melanoma in collaboration with the transplant team should be considered. Larger studies utilizing uniform staging criteria or at minimum Breslow depth, are required to assess true risk and outcome of MM in the immunosuppressed transplant population. Emphasis remains on patient education and regular screening to provide early detection of MM.

    Original languageEnglish
    Pages (from-to)1297-1304
    Number of pages8
    JournalAmerican Journal of Transplantation
    Volume10
    Issue number5
    DOIs
    Publication statusPublished - 2010

    Keywords

    • Melanoma
    • skin cancer
    • solid organ transplant
    • AMERICAN JOINT COMMITTEE
    • MALIGNANT-MELANOMA
    • RENAL-TRANSPLANTATION
    • SKIN-CANCER
    • ALLOGRAFT RECIPIENTS
    • MEDICAL PROGRESS
    • UNITED-STATES
    • DONOR CANCER
    • NODE BIOPSY
    • TRANSMISSION

    Cite this

    Zwald, F. O., Christenson, L. J., Billingsley, E. M., Zeitouni, N. C., Ratner, D., Bordeaux, J., ... ITSCC (2010). Melanoma in solid organ transplant recipients. American Journal of Transplantation, 10(5), 1297-1304. https://doi.org/10.1111/j.1600-6143.2010.03078.x
    Zwald, F. O. ; Christenson, L. J. ; Billingsley, E. M. ; Zeitouni, N. C. ; Ratner, D. ; Bordeaux, J. ; Patel, M. J. ; Brown, M. D. ; Proby, C. M. ; Euvrard, S. ; Otley, C. C. ; Stasko, T. ; ITSCC. / Melanoma in solid organ transplant recipients. In: American Journal of Transplantation. 2010 ; Vol. 10, No. 5. pp. 1297-1304.
    @article{6ce35823b80a42f9964ce7f3f7d44801,
    title = "Melanoma in solid organ transplant recipients",
    abstract = "This manuscript outlines estimated risk and clinical course of pretransplant MM, donor-transmitted MM and de novo MM posttransplantation and includes an analysis of risk factors for metastasis, data from clinical studies and current and proposed management. MM in situ and thin melanoma (< 1 mm) in the transplant population has similar recurrence and survival estimates to those in the general population. A minimum wait time of 2 years prior to transplantation is suggested for MM with a Breslow depth < 1 mm and no clinical evidence of metastasis. More advanced MM may adopt a more aggressive course in transplant recipients. Sentinel lymph node biopsy may be of additional prognostic benefit. Revision of immunosuppression in the management of de novo melanoma in collaboration with the transplant team should be considered. Larger studies utilizing uniform staging criteria or at minimum Breslow depth, are required to assess true risk and outcome of MM in the immunosuppressed transplant population. Emphasis remains on patient education and regular screening to provide early detection of MM.",
    keywords = "Melanoma, skin cancer, solid organ transplant, AMERICAN JOINT COMMITTEE, MALIGNANT-MELANOMA, RENAL-TRANSPLANTATION, SKIN-CANCER, ALLOGRAFT RECIPIENTS, MEDICAL PROGRESS, UNITED-STATES, DONOR CANCER, NODE BIOPSY, TRANSMISSION",
    author = "Zwald, {F. O.} and Christenson, {L. J.} and Billingsley, {E. M.} and Zeitouni, {N. C.} and D. Ratner and J. Bordeaux and Patel, {M. J.} and Brown, {M. D.} and Proby, {C. M.} and S. Euvrard and Otley, {C. C.} and T. Stasko and ITSCC",
    year = "2010",
    doi = "10.1111/j.1600-6143.2010.03078.x",
    language = "English",
    volume = "10",
    pages = "1297--1304",
    journal = "American Journal of Transplantation",
    issn = "1600-6135",
    publisher = "Wiley",
    number = "5",

    }

    Zwald, FO, Christenson, LJ, Billingsley, EM, Zeitouni, NC, Ratner, D, Bordeaux, J, Patel, MJ, Brown, MD, Proby, CM, Euvrard, S, Otley, CC, Stasko, T & ITSCC 2010, 'Melanoma in solid organ transplant recipients', American Journal of Transplantation, vol. 10, no. 5, pp. 1297-1304. https://doi.org/10.1111/j.1600-6143.2010.03078.x

    Melanoma in solid organ transplant recipients. / Zwald, F. O.; Christenson, L. J.; Billingsley, E. M.; Zeitouni, N. C.; Ratner, D.; Bordeaux, J.; Patel, M. J.; Brown, M. D.; Proby, C. M.; Euvrard, S.; Otley, C. C.; Stasko, T.; ITSCC.

    In: American Journal of Transplantation, Vol. 10, No. 5, 2010, p. 1297-1304.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Melanoma in solid organ transplant recipients

    AU - Zwald, F. O.

    AU - Christenson, L. J.

    AU - Billingsley, E. M.

    AU - Zeitouni, N. C.

    AU - Ratner, D.

    AU - Bordeaux, J.

    AU - Patel, M. J.

    AU - Brown, M. D.

    AU - Proby, C. M.

    AU - Euvrard, S.

    AU - Otley, C. C.

    AU - Stasko, T.

    AU - ITSCC

    PY - 2010

    Y1 - 2010

    N2 - This manuscript outlines estimated risk and clinical course of pretransplant MM, donor-transmitted MM and de novo MM posttransplantation and includes an analysis of risk factors for metastasis, data from clinical studies and current and proposed management. MM in situ and thin melanoma (< 1 mm) in the transplant population has similar recurrence and survival estimates to those in the general population. A minimum wait time of 2 years prior to transplantation is suggested for MM with a Breslow depth < 1 mm and no clinical evidence of metastasis. More advanced MM may adopt a more aggressive course in transplant recipients. Sentinel lymph node biopsy may be of additional prognostic benefit. Revision of immunosuppression in the management of de novo melanoma in collaboration with the transplant team should be considered. Larger studies utilizing uniform staging criteria or at minimum Breslow depth, are required to assess true risk and outcome of MM in the immunosuppressed transplant population. Emphasis remains on patient education and regular screening to provide early detection of MM.

    AB - This manuscript outlines estimated risk and clinical course of pretransplant MM, donor-transmitted MM and de novo MM posttransplantation and includes an analysis of risk factors for metastasis, data from clinical studies and current and proposed management. MM in situ and thin melanoma (< 1 mm) in the transplant population has similar recurrence and survival estimates to those in the general population. A minimum wait time of 2 years prior to transplantation is suggested for MM with a Breslow depth < 1 mm and no clinical evidence of metastasis. More advanced MM may adopt a more aggressive course in transplant recipients. Sentinel lymph node biopsy may be of additional prognostic benefit. Revision of immunosuppression in the management of de novo melanoma in collaboration with the transplant team should be considered. Larger studies utilizing uniform staging criteria or at minimum Breslow depth, are required to assess true risk and outcome of MM in the immunosuppressed transplant population. Emphasis remains on patient education and regular screening to provide early detection of MM.

    KW - Melanoma

    KW - skin cancer

    KW - solid organ transplant

    KW - AMERICAN JOINT COMMITTEE

    KW - MALIGNANT-MELANOMA

    KW - RENAL-TRANSPLANTATION

    KW - SKIN-CANCER

    KW - ALLOGRAFT RECIPIENTS

    KW - MEDICAL PROGRESS

    KW - UNITED-STATES

    KW - DONOR CANCER

    KW - NODE BIOPSY

    KW - TRANSMISSION

    U2 - 10.1111/j.1600-6143.2010.03078.x

    DO - 10.1111/j.1600-6143.2010.03078.x

    M3 - Article

    VL - 10

    SP - 1297

    EP - 1304

    JO - American Journal of Transplantation

    JF - American Journal of Transplantation

    SN - 1600-6135

    IS - 5

    ER -

    Zwald FO, Christenson LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux J et al. Melanoma in solid organ transplant recipients. American Journal of Transplantation. 2010;10(5):1297-1304. https://doi.org/10.1111/j.1600-6143.2010.03078.x